Post-vaccination Syncope: Follow-up Survey of Reports to Vaccine Adverse Event Reporting System (VAERS) 44 th National Immunization Conference 04-19-2010.

Slides:



Advertisements
Similar presentations
The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.
Advertisements

1 Cover page Let’s Review Changes in CDC Recommendations in 2011 Carolee’s Corner January 2012 MPCA
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
Julianne Gee, MPH Immunization Safety Office
Maryland Department of Health and Mental Hygiene.
Improving The Clinical Care of Children and Adolescents With Mild Traumatic Brain Injury Madeline Joseph, MD, FACEP, FAAP Professor of Emergency Medicine.
Adolescent Vaccines What every parent needs to know!
Fainting and Anaphylaxis Needlestick Injuries Bryna Warshawsky, MDCM, FRCPC Associate Medical Officer of Health Middlesex-London Health Unit.
1 VAERS Reporting During a Large Scale Vaccination Clinic in Chicago Lessons Learned Chicago Department of Public Health Immunization Program Lorraine.
Module 6 Inactivated poliovirus vaccine AEFI monitoring Training for Inactivated Poliovirus Vaccine (IPV) introduction.
Inflammatory Low Back Pain
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
SYNCOPE. 42 yo man comes to the ER with syncope He was standing in line waiting to renew his driver’s license Felt tired, nauseated, few seconds later.
Case Study: Jennifer and James Amy B. Middleman, MD, MSEd, MPH Assistant Professor, Department of Pediatrics, Adolescent Medicine Section, Baylor College.
Vaccine Safety Concerns  Past of vaccines  Now most parents have never seen a case of diphtheria, measles, or other once- common diseases.  They therefore.
Varicella Zoster Virus Herpesvirus (DNA) Primary infection results in varicella (chickenpox) Recurrent infection results in herpes zoster (shingles) Short.
What's New on the Child and Adolescent Immunization Schedules William L. Atkinson, MD, MPH National Center for Immunization and Respiratory Diseases William.
Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.
Jeff Neccuzi, Director Division of Immunization Services WV Bureau for Public Health.
Child Care Provider Parents Siblings GrandparentsHealthcare Worker.
VAERS Analysis SaneVax Inc. ©2012. Total Adverse Events Gardasil (HPV4)was approved for use in June This chart represents the vaccines most frequently.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Traumatic Brain Injury Definition
The potential impact of adherence to a guideline on the utilization of head CT scans in traumatic head injury patients. Frederick K. Korley M.D.
Use of 12 weekly doses of isoniazid and rifapentine for the treatment of latent tuberculosis − Connecticut , Kelley Bemis, MPH CDC/CSTE Applied.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
Carol Mansfield, M.D., M.P.H. Winthrop Pediatrics and Adolescent Medicine.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
The Hilltop Institute was formerly the Center for Health Program Development and Management. Emergency Room Use by Individuals with Disabilities Enrolled.
Approved: 9 Jun DoD Leader’s Briefing: Force Health Protection Against Anthrax.
June 2010 California Pertussis Update. Pertussis Background Pertussis is the most poorly controlled vaccine- preventable disease  Incidence increasing.
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.
Differential Diagnosis. Salient Features Often observed to be absent minded Brief episodes of blank staring and inattention Eye blinking Reflex scratching.
Concussion Overview for NFHS Point of Emphasis for 2010 Presented by Dr. Dariusz Wolman.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
Heat Stress Management. Objective  It is the policy of CSP to provide equipment necessary to prevent injury in the event of exposure to high ambient.
Injury Epidemiology Moving from Descriptive to Analytic Research Approaches readings Thomas Songer, PhD University of Pittsburgh
Presentation Outline Introduction Reasons to Immunize Adults: Make the Case Myths vs. Facts Barriers to Adult Immunization The Ask Adult Immunization Resources.
HEPATITIS A EISENMAN ARIE, M.D Department of Internal Medicine B Rambam Medical Center Haifa, Israel
Update on the febrile seizure signal after influenza vaccine David Martin, MD, MPH Pharmacovigilance Branch Division of Epidemiology Office of.
Pertussis and Pertussis Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
Seizures & Epilepsy 10-4 training 10 Slides, 4 minutes Lehigh/Hanson Region West Safety and Health.
CAUSING BACTERIAL MENINGITIS Cochlear Implants. Cochlear Implant Is a surgically implanted device that helps overcome problems in the inner ear, or cochlea.
Progress in adolescent vaccination coverage levels in the United States National Immunization Conference Washington, DC March 31, 2011 Shannon Stokley,
Vaccination Administration Errors Reported to the Vaccine Adverse Event Reporting System (VAERS) Elaine R. Miller, RN, MPH Beth Hibbs, RN, MPH Barbara.
1 Syncope and Related Injuries after Vaccination Wan-Ting Huang, MD Immunization Safety Office Office of the Chief Science Officer The 42 nd National Immunization.
National Immunization Conference March 30, 2011 Elaine R. Miller, RN, MPH Beth Hibbs, RN, MPH What Healthcare Providers Need to Know about the Vaccine.
1 Review of the Vaccine Adverse Event Reporting System (VAERS) Beth Hibbs RN, MPH; Elaine Miller RN, MPH Immunization Safety Office (ISO) Division of Healthcare.
TM Influenza Vaccine Safety in Children: Data from VAERS John Iskander MD MPH Gina Mootrey DO MPH Penina Haber MPH Roseanne English-Bullard BS.
Where Has All the Pertussis Gone? Pertussis Trends from and the Potential Early Impact of Tdap Vaccination National Immunization Conference Dallas,
Children’s Outcomes Research Program The Children’s Hospital Aurora, CO Children’s Outcomes Research Program The Children’s Hospital Aurora, CO Colorado.
1 Janine M. Jurkowski, PhD * Dayna M. Maniccia, MS * Steven J. Samuels, PhD * Deborah A. Spicer, MPH § Barbara A. Dennison, MD §* * University at Albany,
Status Epilepticus Presenting After Traumatic Brain Injury in Infants Kurz, J. E.1; Zelleke, T.1; Carpenter, J.1; Dean, N.2; Singh, J.1; Kadom, N.3; Gaillard,
Fainting First Aid Mahmoud Maharmeh.
Learning Collaborative #5 September 2016
9. Introduction to signal detection
ACIP Feb , 2007 Guillain-Barré Syndrome (GBS) Among Recipients of Meningococcal Conjugate Vaccine (MCV4,Menactra®) Update Oct Jan Robert.
CD-JEV AEFI monitoring
Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events
Module 6 Rotavirus vaccine AEFI monitoring
Women’s Health Care and Education Coalition
Pediatric Inactivated Influenza Vaccine Safety VAERS Reports for Trivalent Inactivated Influenza Vaccine (TIV) in Infants/Toddlers Ann McMahon, MD, MS.
Module 6 Rotavirus vaccine AEFI monitoring
Managing Seizures in the Classroom
Module 6 Rotavirus vaccine AEFI monitoring
Module 6 Rotavirus vaccine AEFI monitoring
Module 6 Rotavirus vaccine AEFI monitoring
Immunization Safety Office (ISO) National Immunization Program (NIP)
Presentation transcript:

Post-vaccination Syncope: Follow-up Survey of Reports to Vaccine Adverse Event Reporting System (VAERS) 44 th National Immunization Conference Angela Calugar, MD, MPH Elaine R. Miller, RN, MPH Alison Rue-Cover, BSN, MPH LaTonia Alexander, MS Immunization Safety Office DHQP/NCEZID/CDC 1

 Background –Post-vaccination syncope –Recommendations to prevent post-vaccination syncope –VAERS database  Evaluation of post-vaccination syncope reported to VAERS  Conclusions 2 Presentation Outline

Post-vaccination Syncope Syncope is a transient loss of consciousness due to decreased perfusion to the brain; diverse etiology Vasovagal reaction –Sudden decrease in blood pressure which deprives the brain of sufficient oxygen causing dizziness (pre-syncope) or a brief loss of consciousness (syncope) –Is the most common cause of syncope (~20 to 35% percent of cases), particularly in patients without apparent cardiac or neurologic disease –Recovery is generally spontaneous –Potential for secondary traumatic injuries from falling 3

Features of the Vasovagal Episodes  The episodes are typically recurrent, usually occur when the person is exposed to a specific trigger  Prodrome lasts for at least a few seconds: lightheadedness, nausea, sweating, ringing in the ears (tinnitus), uncomfortable feeling in the heart, weakness and visual disturbances  Consciousness is lost typically when the person is sitting up or standing  If the person tries to sit or stand when they wake up, they may faint again 4

Measures to Prevent Vasovagal Reaction and Syncope (Limited Evidence)  Coffee consumption before blood donation had protective effect  Fluid loading, muscle tensing, distraction were observed to be beneficial  Providing more personal attention to an anxious patient  Quickly recognize and reverse mild reaction (prodrome) before the procedure  Obtain information about previous history of vasovagal reaction  Observing a 15-minute waiting period after vaccination 5

Recommendations to Prevent Post-vaccination Syncope:  2006 Advisory Committee on Immunization Practices: –“…providers should strongly consider observing patients for 15 minutes after they are vaccinated “ (MMWR 55(No.RR-15): 2006)  2009 Red Book: –“Personnel should be aware of presyncopal manifestations and take appropriate measures to prevent injuries… –Having vaccine recipients sit or lie down for 15 minutes after immunization could avert many syncopal episodes and secondary injuries “ (American Academy of Pediatrics. Active immunization. In: Pickering LK, ed 2009 Red Book) 6

Vaccine Adverse Event Reporting System (VAERS)  National post-licensure passive surveillance system for vaccine adverse events (AEs) operated by CDC and FDA  Anyone can report to VAERS, e.g. vaccine administrator, or another healthcare provider, a patient or his/her parent or designated guardian, a manufacturer, etc.  Advantages –Covers US population –Permits monitoring for known AEs –Detects signals for previously unrecognized /rare AEs –Generates hypothesis  Limitations –Underreporting –Stimulated reporting due to media attention and other factors –Incomplete data –Lack of availability of denominator data 7

VAERS Published Data on Syncope Following Vaccination VAERS reports of post-vaccination syncope associated with fall and injury including one death and two severe head injuries (Woo EJ, et al. Fatal syncope-related fall after immunization. Archives of Pediatrics and Adolescent Medicine. 159(11):1083, November 2005.) VAERS % of the 463 syncope reports were associated with recently recommended adolescent vaccines: Menactra (MCV4), Tetanus, diphtheria and acellular pertussis (Tdap), and Gardasil (HPV). (CDC. MMWR 2008; 57 (No.17)

9 Post-vaccination Syncope: Survey to Evaluate Cases Reported to VAERS between 01/01/2009 and 08/31/2009

Survey Objectives  Phone survey of a convenience sample of VAERS cases reported between 01/01/2009 and 08/31/2009 to collect information about post-vaccination syncope: –Visible signs and symptoms before, during, and after the syncope, and health outcomes –Circumstances under which the syncope episode occurred (position the patient was in, onset interval, etc.) –Measures implemented by providers to prevent syncope –Other related descriptive data 10

Definitions  “Reporter”: a person who submitted a report to VAERS about post- vaccination syncope  “Case”: a person who experienced post-vaccination syncope and eligible for survey after applying exclusion/inclusion criteria –Only cases with loss of consciousness within 1 hour from immunization were considered for our survey  Serious AEs: –death, life-threatening illness, permanent disability, hospitalization, prolongation of an existing hospitalization  Medical Dictionary for Regulatory Activities (MedDRA) –To code clinical signs and symptoms in VAERS database 11

12 Methods  Identification of VAERS reports –Search in VAERs data base for US primary reports  Submitted between 01/01/2009 to 08/31/2009  MedDRA codes “syncope” or “syncope vasovagal”  Serious and Non-Serious  Onset interval same day of vaccination  Unrestricted by age, gender, and vaccine type  Excluded –Manufacturer reports* –Other reports with incomplete information  Phone survey of a convenience sample of reporters (18 years and older) who submitted cases of syncope (onset within 1 hour of vaccination); interviews conducted in September-November 2009 *Usually are lacking critical identifiable and contact information for the reporter and the vaccine recipient

Phone Survey Case Inclusion 13 Initially identified reports, N=381 (adverse event on day “0”, all gender, all ages, all vaccines) Manufacturer reports excluded, N=83 (usually incomplete) Other reports excluded, N=55 (incomplete reports and reports with onset longer than 1hour) Eligible reports, N=243 (called 142 most recently submitted reports; 28 non- responders) Syncope cases included in the survey, N=114 Serious reports, n=3 (3%) Non-serious reports, n=111 (97%)

Survey to Evaluate Cases Reported to VAERS between 01/01/2009 and 08/31/2009: Preliminary Results 14

Reporters (N=114) and Vaccine Administration Settings*  Reporters of the syncope: –Healthcare providers (n=110) –Parent (n=1) –Patient (n=1) –Other (n=2) * VAERS Cases (N=114) submitted between 01/01/2009 to 08/31/

Distribution of Syncope Cases (N=114) by Gender and Age Gendern%Age range, years Mean age Median age Males2118% Females9281% Unknown11%14 16

Characteristics of the Syncope Cases (N=114) No.% Previous history of syncope Yes2421% No5649% Unknown3430% Patient had beverage or food intake prior to immunization Yes3430% No2320% Unknown5750% 17

Onset Time and Event Distribution by Age Group 18 Syncope Distribution by Age Group

Distribution of Syncope Cases by Vaccines Type* 19 Number of patients Vaccines administered alone or in combination *Survey reports to VAERS between 01/01/2009 and 08/31/2009

What position was the patient in at the time of the syncope? 20

Where did the syncope occur? 21 Location Where Syncope Occurred Number of Patients

Was the patient asked by the provider to wait after receiving vaccines? 22

Reported Signs and Symptoms Associated with Syncope Episode Did you witness the fainting episode? –Yes- 79 –No -28, –Unknown-7 Reported symptoms in observed cases:  Pale face, n=58  Anxiety, n=38  Nausea, n=29  Sweating, n=23  Vomiting, n=4  Severe inject. site pain, n=4  Tonic clonic movements, n=36 (46% of observed cases) 23

Reported Signs and Symptoms Associated with Syncope Episode Did you witness the fainting episode? –Yes- 79 –No -28, –Unknown-7 Reported symptoms in observed cases:  Pale face, n=58  Anxiety, n=38  Nausea, n=29  Sweating, n=23  Vomiting, n=4  Severe inject. site pain, n=4  Tonic clonic movements, n=36 (46% of observed cases) 24

Patient Outcomes Syncope Cases*  Recovered completely=72  Fell but was not injured=12  Fell and was injured=31 –Including 3 Serious Reports  Type of injuries: laceration to head, abrasion to face (eyebrow, lip), lacerations to face,abrasion to clavicle, broken noses, blows to the head and neck *Some cases are listed under two categories. Reported to VAERS between 01/01/2009 and 08/31/2009: 25

Patient Outcomes: Serious Cases (n=3) 17 year old female had vomiting for a day, followed by nausea for 4 days, and continued feeling sick and weak for 3 weeks. The patient had a prior history of syncope after vaccination with associated tonic clonic movements; was referred to neurologist. 13 year old female syncopized with tonic-clonic movements, described an aura and a brief post-ictal period within 5 min after vaccination. She was standing at the onset and fell backwards hitting her head on the floor. Pt was hospitalized for 1 day in epilepsy unit, EEG and MRI normal. Is followed up by neurologist. 13 year old female walked out of exam room and passed out 5-7 min after injection. Experienced head injury; was evaluated in ER and observed for 23 hours in the hospital. CT negative. 26

Waiting policy after Vaccination  Did your office have a policy for patients to wait after all vaccines (at the time this pt fainted)? Yes-44 No-56 Unknown-14  As a result of the syncopal episode, nine providers stated that they changed their policy to institute a waiting period after vaccination. 27

Limitations  Convenience sample is not necessarily representative of the total population of post immunization syncope cases  Recall bias: survey was conducted months after the syncope event occurred  VAERS data is subject to underreporting and stimulated over-reporting bias –Potential for underreporting for syncope if cases have been miscoded as anaphylaxis or seizure and these would not have been detected by our search –Potential stimulated over-reporting for syncope cases following HPV4 vaccine because of high media coverage and increased public attention 28

Limitations (cont.)  Possible overrepresentation of several categories: –Healthcare Providers accounted for 110/114 reporters; this might be a sign of increased awareness about VAERS in healthcare workers –The predominance of female cases could be a result of higher number of HPV4 vaccine administered in US females; 3-dose series recommendation –High distribution of syncope after HPV4, MCV4, and Tdap vaccines could reflect a recent introduction of these vaccines to the immunization schedule of children and adolescents 29

Conclusions  Post-vaccination syncope remains a concern –Secondary injuries with serious outcomes  May affect vaccine acceptance behavior  Current ACIP and AAP recommendations for a 15-minute waiting and observation period following vaccination –Increase awareness among healthcare providers  Healthcare providers consider additional preventive measures –Based on their own observations –Based on medical literature (studies in blood donors and trauma centers’ patients)  Important to recognize pre-syncope signs and symptoms  Refined evidence-based prevention recommendations are needed 30

Acknowledgements  Immunization Safety Office –Karen Broder –Maria Cano –Beth Hibbs –Claudia Vellozzi –Oidda Museru –Yenlik Zheteyeva  Immunization Services Division –Robin Curtis –Andrew Kroger 31

Disclosure  The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.  CDC investigators wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters 32

Places Where Patient Fainted, Selected Examples  “spent over 15 min in waiting area; fainted after that in the middle of being briefed about the shot  after a brief waiting period fainted while walking to the parking lot  waited ~5 min in the hall, fainted near front door while leaving  waited in exam room 10 min, got up to leave exam room and fainted at the door of the exam room  standing while brother got vaccinated  was waiting with his sister after vaccination, she got dizzy and had to sit in chair, then he fainted. He was standing up when he fainted, father caught him partially” 33

Syncope Following Immunization: Increase in Reporting to VAERS* “…increase in post-vaccination syncope and secondary injuries suggests that adherence to the 15-minute post-vaccination observation period and its efficacy in preventing syncope- related injuries should be evaluated systematically. ” (CDC. Syncope after vaccination United States. January 2005-July MMWR 2008; 57 (No.17) *CDC unpublished data: automated search in VAERS, U.S. primary reports only, unrestricted by age, vaccine, or gender 34

Survey Instrument  Questions on the following: –Patient demographics –Immunization setting –Waiting policy for immunizations –Vaccines administered –Patient position during immunization and at the time of syncope –Signs and symptoms associated with syncope –Onset interval –Outcome –Previous history of syncope –Previous food intake –Suggestions for prevention 35

demographics AE vax

Suggestions from Healthcare Providers on Prevention Measures  Give candy, lollypops after the immunizations  Have the patient lie down for the shot and get up slowly  Have the patient eat prior to immunizations. One office refuses to give vaccinations if the patient hasn’t eaten that day. They remind the pt to eat when they make the appointment reminder call and if the pt still hasn’t eaten, they send them to a fast food restaurant located in their building before they will vaccinate.  Have a room with lounge chairs for patients to wait in after vaccines. Many providers stated they needed to keep exam rooms clear for the next patient so that they would not get behind schedule.  Do not allow teens to drive themselves home. Tell teens prior to their arrival that they have to have a driver take them home after immunizations.  In general, take more time with patients. 37

Onset Time From Vaccination to Syncope by Age Group 38

VAERS Published Data on Syncope Following Vaccination VAERS  63% of the 463 syncope reports were associated with recently recommended adolescent vaccines: Menactra (MCV4), Tetanus, diphtheria and acellular pertussis (Tdap), and Gardasil (HPV). (CDC. MMWR 2008; 57 (No.17 ) VAERS reports of post-vaccination syncope associated with fall and injury including one death and two severe head injuries ( Woo EJ, et al. Fatal syncope-related fall after immunization. Archives of Pediatrics and Adolescent Medicine. 159(11):1083, November 2005.) VAERS % of syncopal episodes that occurred within 15 minute after vaccination were associated with tonic clonic movements. ( Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med. 1997:151(3):255-9.)